MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyae323

Медицинская библиотека · The oncologist · 2025

Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.

Chung Vincent, Alistar Angela, Becerra Carlos, Kasi Anup, Borazanci Erkut, Jameson Gayle S, Roe Denise J, Wertheim Betsy C, Cridebring Derek, Truitt Morgan, Downes Michael, Barrett Michael T, Korn Ron, Lee Keehoon, Han Haiyong, Evans Ronald, Von Hoff Daniel D

СтатьяРандомизированное исследованиеКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

LESSONS LEARNED: Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life.

BACKGROUND

Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with the tumor microenvironment playing a key role in immune resistance. In preclinical studies, vitamin D receptor (VDR) agonists have been shown to sensitize pancreatic tumors to PD-1 blockade.

METHODS

This was a randomized, double-blinded, placebo-controlled, phase II trial to evaluate pembrolizumab with or without paricalcitol as maintenance therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Participants were ≥18 years; histologically or cytologically confirmed metastatic PDAC showing no disease progression after frontline systemic therapy, and achieving maximal cytoreduction (eg, with no further antitumor effect), Eastern Cooperative Oncology Group (ECOG) status of 0 or 1; adequate organ function. Study treatment included: pembrolizumab 200 mg IV every 3 weeks and either paricalcitol 25 mcg IV 3 times per week or placebo. The primary objective was to evaluate 6-month progression free survival (PFS). Secondary objectives include evaluating the toxicity of the combination and overall survival (OS).

RESULTS

There was no significant difference in 6-month PFS, median PFS, median OS, nor treatment-related AEs between the 2 arms.

CONCLUSIONS AND RELEVANCE: Paricalcitol did not improve the efficacy of pembrolizumab likely related to its short half-life of only 5-7 hours. Microbiome analysis revealed significant difference between long-term (>12 weeks) and short-term (<12 weeks) survival groups across treatment arms. Modulation of the tumor microenvironment will likely require more sustained VDR activity.

TRIAL REGISTRATION: Clinicaltrials.gov, ID: NCT03331562.

Для цитирования: Chung Vincent, Alistar Angela, Becerra Carlos, Kasi Anup, Borazanci Erkut, Jameson Gayle S, Roe Denise J, Wertheim Betsy C, Cridebring Derek, Truitt Morgan, Downes Michael, Barrett Michael T, Korn Ron, Lee Keehoon, Han Haiyong, Evans Ronald, Von Hoff Daniel D. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.. The oncologist. 2025. DOI: 10.1093/oncolo/oyae323.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.